Deaf children can now hear thanks to a new treatment that repairs a defective gene. Researchers associated with the biotech ...

CRISPR Therapeutics is still losing money, but it has an expanding pipeline. The biotech is seeing growing sales from its one product, Casgevy. It also has other promising drug candidates in its ...

At the upcoming annual meeting of the American Society of Gene and Cell Therapy, scientists from Huidagene Therapeutics will share an update on the development of their ...

CRISPR Therapeutics (Nasdaq: CRSP) today reported financial results for the first quarter ended March 31, 2026. “The first ...

Lipid nanoparticles, or LNPs, best known as the delivery vehicle for the COVID-19 mRNA vaccines received by billions of people, are now at the center of a much larger medical revolution. Researchers ...

Scientists have unveiled a CRISPR-based tool, ThermoCas9, capable of pinpointing and removing tumor DNA by detecting cancer-specific chemical markers, potentially sparing healthy cells. In parallel, ...

(RTTNews) - Vertex Pharmaceuticals (VRTX), Thursday reported compelling long-term data for its CRISPR/Cas9 gene-edited therapy, PrCASGEVY, at the EHA Congress. In sickle cell disease trials, 95.6 ...

In the world of biopharmaceutical innovation, 2024 will be remembered as CRISPR’s breakout year. In the spring, five patients with sickle cell disease began treatment with Casgevy, the first ...

Clustered regularly interspaced short palindromic repeats (CRISPR) and CRISPR-associated (Cas) proteins are core components of fast-evolving therapeutic gene editing tools. Scientists have used CRISPR ...

In back-to-back studies published in Nature, researchers from Purdue University and Columbia University report a naturally evolved gene-editing system that can activate genes, offering an advantage ...